VIVUS (VVUS) Lowered to Strong Sell at ValuEngine

ValuEngine lowered shares of VIVUS (NASDAQ:VVUS) from a sell rating to a strong sell rating in a report published on Friday morning.

VIVUS (VVUS) opened at $0.65 on Friday. The company has a market capitalization of $69.36, a price-to-earnings ratio of 1.87 and a beta of 0.77. The company has a debt-to-equity ratio of 643.86, a current ratio of 7.47 and a quick ratio of 7.09. VIVUS has a 1 year low of $0.61 and a 1 year high of $1.47.

VIVUS (NASDAQ:VVUS) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.07. The firm had revenue of $15.19 million during the quarter, compared to analyst estimates of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.09) EPS. research analysts anticipate that VIVUS will post -0.32 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the stock. AJO LP purchased a new position in VIVUS during the 2nd quarter worth $3,329,000. Acadian Asset Management LLC grew its stake in VIVUS by 70.9% during the 2nd quarter. Acadian Asset Management LLC now owns 1,837,822 shares of the biopharmaceutical company’s stock worth $2,241,000 after buying an additional 762,392 shares during the last quarter. OxFORD Asset Management LLP grew its stake in VIVUS by 14.0% during the 3rd quarter. OxFORD Asset Management LLP now owns 1,059,382 shares of the biopharmaceutical company’s stock worth $1,040,000 after buying an additional 129,871 shares during the last quarter. Russell Investments Group Ltd. grew its stake in VIVUS by 166.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 395,527 shares of the biopharmaceutical company’s stock worth $392,000 after buying an additional 246,927 shares during the last quarter. Finally, Northern Trust Corp grew its stake in VIVUS by 16.8% during the 2nd quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 39,473 shares during the last quarter. Hedge funds and other institutional investors own 31.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/05/vivus-vvus-lowered-to-strong-sell-at-valuengine.html.

VIVUS Company Profile

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about VIVUS Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for VIVUS Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit